NOVO.B.DK

296.6

-1.38%↓

GMAB.DK

1,712.5

+4.13%↑

COLO.B.DK

406.8

+1.78%↑

HLUNB.DK

41.82

-1.51%↓

AMBUB.DK

62.3

+0.4%↑

NOVO.B.DK

296.6

-1.38%↓

GMAB.DK

1,712.5

+4.13%↑

COLO.B.DK

406.8

+1.78%↑

HLUNB.DK

41.82

-1.51%↓

AMBUB.DK

62.3

+0.4%↑

NOVO.B.DK

296.6

-1.38%↓

GMAB.DK

1,712.5

+4.13%↑

COLO.B.DK

406.8

+1.78%↑

HLUNB.DK

41.82

-1.51%↓

AMBUB.DK

62.3

+0.4%↑

NOVO.B.DK

296.6

-1.38%↓

GMAB.DK

1,712.5

+4.13%↑

COLO.B.DK

406.8

+1.78%↑

HLUNB.DK

41.82

-1.51%↓

AMBUB.DK

62.3

+0.4%↑

NOVO.B.DK

296.6

-1.38%↓

GMAB.DK

1,712.5

+4.13%↑

COLO.B.DK

406.8

+1.78%↑

HLUNB.DK

41.82

-1.51%↓

AMBUB.DK

62.3

+0.4%↑

Inicio・Lista de Acciones・Zealand Pharma A-S

Zealand Pharma A-S

Cerrado

334.5 -3.6

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

330.8

Máximo

347

Métricas clave
By Trading Economics
Ingresos	25M -379M
Ventas	19M 69M
P/B Media del Sector	3.425 49.8
BPA	-5.19
Margen de beneficios	-550.12
Empleados	481
EBITDA	-150M -503M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+25.15% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-6.8B 21B
Apertura anterior	338.1
Cierre anterior	334.5

Zealand Pharma A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 mar 2026, 09:24 UTC

Principales Movimientos del Mercado

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

6 mar 2026, 07:22 UTC

Charlas de Mercado

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

Comparación entre iguales

Cambio de precio

Zealand Pharma A-S previsión

Precio Objetivo

By TipRanks

25.15% repunte

Estimación a 12 Meses

Media 270.582 DKK 25.15%

Máximo 270.568 DKK

Mínimo 270.568 DKK

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Zealand Pharma A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

1 ratings

Comprar

Mantener

Vender

De acuerdo con 1 analistas que ofrecen calificaciones bursátiles a para Zealand Pharma A-S Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.